Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CLS2702C + CLS2702D is an investigational combination therapy studied for the prevention of esophageal stenosis (narrowing) following endoscopic submucosal dissection (ESD) in patients with superficial esophageal cancer, particularly in those at increased risk from steroid therapy. The precise chemical nature, modality, or mechanistic details of CLS2702C and CLS2702D are not specified in publicly available trial registries, and neither active ingredient nor pharmacological class is clarified by clinical trial or patent records. The combination is being evaluated as a topical or local intervention specifically for esophageal healing post-ESD, with no evidence it is a systemically administered or traditional pharmaceutical drug[1][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on CLS2702C + CLS2702D.